This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
The acquisition allows cliexa to meet GI customers with an end-to-end automated scheduling, reporting and communications platform.
The company currently has 11 locations delivering virtual-supported care, but now plans to open "several" more in the first half of 2021.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
The startup will now move onto a larger pivotal trial of the neuromodulation therapy, which received a Breakthrough Device Designation from the FDA in January.
The digital MSK company is looking to bundle the non-invasive, non-addictive pain reduction device alongside the rest of its employer-focused offerings.
Also: Mantra Health appoints medical director; Deep 6 AI creates VP of life sciences role.
Providers will be able to have in-app live video conversations with chronic pain and movement disorder patients, as well as prescribe new settings for their neuromodulation therapies from afar.
The system delivers its results to a companion app in about 20 minutes, according to the agency.
Also: Oscar Health IPO dips below expectations; DrChrono's new "all-in-one telehealth app experience."
_0.jpg?itok=YW263h0l)
